Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025545) BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025545 International Application No.: PCT/EP2018/071002
Publication Date: 07.02.2019 International Filing Date: 02.08.2018
IPC:
C07K 16/10 (2006.01) ,C07K 16/28 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08
against material from viruses
10
from RNA viruses
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
GENMAB A/S [DK/DK]; Kalvebod Brygge 43 1560 Copenhagen V, DK
BIONTECH AG [DE/DE]; An der Goldgrube 12 55131 Mainz, DE
Inventors:
ALTINTAS, Isil; NL
SATIJN, David; NL
RADEMAKER, Rik; NL
PARREN, Paul; NL
SAHIN, Ugur; DE
GIESEKE, Friederike; DE
MUIK, Alexander; DE
GRUNWITZ, Christian; DE
Agent:
GENMAB A/S; Kalvebod Brygge 43 1560 DK-Copenhagen V, DK
Priority Data:
PCT/EP2017/06983904.08.2017EP
PCT/EP2018/05294606.02.2018EP
Title (EN) BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
(FR) AGENTS DE LIAISON SE LIANT À PD-L1 ET CD137 ET LEUR UTILISATION
Abstract:
(EN) The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
(FR) La présente invention concerne de nouveaux agents de liaison et leur utilisation en médecine. En particulier, L'invention concerne des agents de liaison tels que des anticorps bispécifiques se liant à PD-L1 humain et CD137 humain. L'invention concerne en outre des utilisations des anticorps de l'invention et des procédés, des constructions d'acide nucléique et des cellules hôtes pour produire des anticorps selon l'invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)